# Apogenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apogenix

- Industry: Biotechnology
- Headquarters: Heidelberg, Germany
- Website: www.apogenix.de
- Total disclosed funding: $62M
- Latest round: Series B (Apr 30, 2008)
- Investors on record: 1

## About

Apogenix, Gmbh is a biopharmaceutical company focused on developing innovative immunotherapeutics for cancer and viral infections, including COVID-19, utilizing advanced technology platforms to enhance immune responses.Apogenix is engaged in the development of immunotherapies targeting cancer and viral infections. The company was founded in Heidelberg, Germany. Its CEO is Thomas Hoeger. Apogenix has successfully completed 11 deals, with the most recent funding round on December 9, 2021, where it secured EUR 20.7 million in Grant funding from the Federal Ministry of Education and Research. The total amount raised by the company amounts to EUR 5.1 million.Apogenix specializes in developing innovative immunotherapeutics aimed at addressing cancer and viral infections, including COVID-19. Its core product, asunercept, is currently in clinical development for treating solid tumors, malignant hematological diseases, and COVID-19. Utilizing the HERA-ligand technology platform, asunercept targets TNFSF-dependent signaling pathways crucial for regulating the immune response, aiming to reduce lymphopenia and inflammatory cell death while restoring anti-tumor immunity. Apogenix targets a global market with its products being evaluated for clinical use in North America, Europe, and parts of Asia.Apogenix's revenue model is structured around partnerships and collaborations with healthcare providers and research institutions, focusing on clinical trials and commercialization of its immunotherapeutic products. Transactions typically involve agreements for treatment provision, including upfront payments, milestone payments based on clinical progress, and royalties from future sales. The company’s flagship product, asunercept, positions it to attract interest from oncologists and hematologists treating patients with solid tumors and blood disorders, supporting the ongoing development of therapies and exploration of new indications in immuno-oncology.Following its recent funding round on December 9, 2021, where Apogenix obtained EUR 20.7 million in Grant funding, the company plans to finance its Phase III clinical trial (ASUCOV) with the CD95 ligand inhibitor and expand its market opportunities. The funding will be utilized to support the development of asunercept and potentially launch new products targeting cancer and viral infections, while exploring opportunities for growth in North America, Europe, and select markets in Asia.

## Funding rounds

- Series B, Apr 30, 2008, $44M — Dievini
- Series A, Nov 1, 2005, $18M — Dievini

## Investors

- Dievini (https://capitalatlas.ai/funds/dievini) — Series A, Series B